These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16395412)

  • 1. Tipranavir.
    Temesgen Z; Cainelli F; Vento S
    Drugs Today (Barc); 2005 Nov; 41(11):711-20. PubMed ID: 16395412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
    Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
    Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
    Kandula VR; Khanlou H; Farthing C
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):9-21. PubMed ID: 15757454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ; Cocohoba JM
    Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
    Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
    AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir: a ritonavir-boosted protease inhibitor.
    Croom KF; Keam SJ
    Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.
    Feiterna-Sperling C; Walter H; Wahn V; Kleinkauf N
    Eur J Med Res; 2009 Jan; 14(1):44-6. PubMed ID: 19258211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.